Two executive directors and a company secretary have resigned from Shanxi Central Pharmaceutical International, leaving the troubled firm with just one director on its board. In an announcement to the stock exchange, Deloitte Touche Tohmatsu - a joint provisional liquidator of the company - said it had received notice that executive directors Hung Shui-nam and Sun Ying-chung had resigned on November 13. The two directors wrote in a letter dated December 15 that they were unable to assure there were no serious matters that should be brought to shareholders' attention. 'When we took over the company's management in August 2003, we found that [it] had experienced enormous financial difficulties,' the letter said. 'We are unable to locate accounting records, worksheets for preparing the group's interim report ... made up to 30 November 2002, important documents such as those relating to the $20 million investment in securities. 'We were unable to contact the founders and former chairman and managing director of the company, and staff members in the PRC subsidiaries of the company were not co-operative.' Deloitte said it had also received a statement from company secretary Ha Chun that he had resigned with effect from November 5 due to 'personal reasons'. As of yesterday, the board of directors of Shanxi Central Pharmaceutical consisted solely of an independent non-executive director, Patrick Ko Siu-shing. Trading in the shares has been suspended since July 25 last year. DBS Bank (Hong Kong) sought a compulsory winding-up order against the company on September 15 this year, following the failure of the company to satisfy a judgment debt of about $32.4 million. The High Court will resume hearings on the petition on February 28.